The Lancet Digest, July 3rd – 9th 2009
The Editorials in this week’s Lancet are about strengthening research capacity in Africa, the declining efficiency of cancer care in the UK and, linked with this week’s Reviews, the current state of health for Indigenous Peoples.
The Articles are about using rivaroxaban to treat acute coronary patients, liraglutide verses exenatide in the glycaemic control of type II diabetes, a study of markers and treatment outcomes for placental-site trophoblastic tumours and treating African trypanosomiasis with Nifurtimox-eflornithine combination therapy (NECT). These Articles are accompanied by Comments on treating acute coronary patients with rivaroxaban, the role of GLP-1 receptors in type II diabeties, the long-term outcomes for placental-site trophoblastic tumours and the NECT trial’s progress in the treatment of sleeping sickness.
This week there is also a two part Review on Indigenous Health. The first part is on diseases and their determinants and the second part is about the underlying causes of the gap in healthcare for indigenous populations. There is also a Perspective on Marlene Kong, one of the few indigenous doctors in Australia.
The World Report is on the grim future for refugees in Pakistan and the threats that loss of land pose to the Sami people of Scandinavia. Also of interesting to global health this week are Comments on Italy’s policies towards health at the upcoming G8 meeting and the Venice Statement on maximising synergies between global health initiatives and health systems. There is also a Perspective on the health problems in US jails and an obituary for Turkan Saylan, a Turkish dermatologist who founded the Turkish Leprosy Relief Association.